Autopsy report · NCT01491633

Dasatinib in Advanced Squamous Cell Lung Cancer

“Safety issues/concerns per DF/HCC PI”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 8 months before it stopped.
• 5 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Dana-Farber Cancer Institute

Sponsor type

University, hospital or other

Conditions

Squamous Cell Lung Cancer

Interventions

Dasatinib

Participants

5

Sites

3

Countries

United States

Trials that died the same way

• A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
  “Safety Issues” (59% match in meaning)
• A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy
  “Safety Review” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.